Trial · NCT00940901

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901, Phase 2, Completed, Johns Hopkins University; results first posted 2017-04-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia. Trials, record NCT00940901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00940901

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
NCT number: NCT00940901
Status: Completed
Phases: Phase 2
Enrollment: 13 participants, actual
Lead sponsor: Johns Hopkins University
Conditions: Sickle Cell Disease, Priapism
Interventions: sildenafil, placebo
First posted: 2009-07-17
Last updated: 2017-04-13
Results first posted: 2017-04-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Greater Than or Equal to a 50% Reduction in Priapic Episodes	change between baseline and 8 weeks post intervention	A "Priapism sexual activity log" was administered to participants. In the log, participants were asked to quantify the number of priapic episodes they had experienced in the previous 2 weeks according to the following scale/tiers: 0 = no episodes, 1 = 1-2 episodes, 2 = 3-4 episodes, 3 = 5-8 episodes and 6 = greater than 20 episodes.
Primary	Greater Than or Equal to a 50% Reduction in Priapic Episodes	change between 8 weeks post intervention and 16 weeks post intervention	A "Priapism sexual activity log" was administered to participants. In the log, participants were asked to quantify the number of priapic episodes they had experienced in the previous 2 weeks according to the following scale/tiers: 0 = no episodes, 1 = 1-2 episodes, 2 = 3-4 episodes, 3 = 5-8 episodes and 6 = greater than 20 episodes.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Greater Than or Equal to a 50% Reduction in Priapic Episodes	change between baseline and 8 weeks post intervention	Intention to treat analysis.	Number of participants	NUMBER
PRIMARY	Greater Than or Equal to a 50% Reduction in Priapic Episodes	change between 8 weeks post intervention and 16 weeks post intervention	3 participants from the Phase 1 Sildenafil group were lost to follow up during the second phase; 2 individuals from the Phase 1 Placebo then sildenafil group were lost to follow up during the second phase.	Number of participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Greater Than or Equal to a 50% Reduction in Priapic Episodes	Sildenafil	3	Number of participants
Greater Than or Equal to a 50% Reduction in Priapic Episodes	Placebo Then Sildenafil	3	Number of participants
Greater Than or Equal to a 50% Reduction in Priapic Episodes	Sildenafil	2	Number of participants
Greater Than or Equal to a 50% Reduction in Priapic Episodes	Placebo Then Sildenafil	3	Number of participants

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Weeks 1-8 (Phase 1)	STARTED	Sildenafil	6
Weeks 1-8 (Phase 1)	STARTED	Placebo Then Sildenafil	7
Weeks 1-8 (Phase 1)	COMPLETED	Sildenafil	6
Weeks 1-8 (Phase 1)	COMPLETED	Placebo Then Sildenafil	7
Weeks 1-8 (Phase 1)	NOT COMPLETED	Sildenafil	0
Weeks 1-8 (Phase 1)	NOT COMPLETED	Placebo Then Sildenafil	0
Week 9-16 (Phase 2)	STARTED	Sildenafil	6
Week 9-16 (Phase 2)	STARTED	Placebo Then Sildenafil	7
Week 9-16 (Phase 2)	COMPLETED	Sildenafil	4
Week 9-16 (Phase 2)	COMPLETED	Placebo Then Sildenafil	4

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events108

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Priapism	Blood and lymphatic system disorders	Sildenafil Phase 1	3	6	3
other	Priapism	Blood and lymphatic system disorders	Placebo Then Sildenafil Phase 1	1	7	1
other	Priapism	Blood and lymphatic system disorders	Sildenafil Phase 2	2	4	3
other	Priapism	Blood and lymphatic system disorders	Placebo Then Sildenafil Phase 2	0	4	0
other	vision trouble	Eye disorders	Sildenafil Phase 1	0	6	0
other	vision trouble	Eye disorders	Placebo Then Sildenafil Phase 1	2	7	2
other	vision trouble	Eye disorders	Sildenafil Phase 2	0	4	0
other	vision trouble	Eye disorders	Placebo Then Sildenafil Phase 2	0	4	0
other	jittery feelings	Musculoskeletal and connective tissue disorders	Sildenafil Phase 1	1	6	1
other	jittery feelings	Musculoskeletal and connective tissue disorders	Placebo Then Sildenafil Phase 1	0	7	0

1 to 10 of 108Source ClinicalTrials.gov

See all 108 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sildenafil Phase 1
Total, all-cause mortality	Placebo Then Sildenafil Phase 1
Total, all-cause mortality	Sildenafil Phase 2
Total, all-cause mortality	Placebo Then Sildenafil Phase 2
Total, other adverse events	Sildenafil Phase 1	5	6
Total, other adverse events	Placebo Then Sildenafil Phase 1	5	7
Total, other adverse events	Sildenafil Phase 2	2	4
Total, other adverse events	Placebo Then Sildenafil Phase 2	0	4
Total, serious adverse events	Sildenafil Phase 1	3	6
Total, serious adverse events	Placebo Then Sildenafil Phase 1	1	7

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00940901

GET https://conductscience.org/api/trials/v1/NCT00940901/events?page=2

API reference For AI assistants